Description
BSE announces securities being added to, moved within, and removed from the Long Term Additional Surveillance Measure (LT-ASM) framework effective March 12, 2026.
Summary
BSE has issued an update to the Long Term Additional Surveillance Measure (LT-ASM) framework, effective March 12, 2026. Five new securities are being added (Part A), two securities are being moved to a higher ASM stage (Part B), none are being moved to a lower stage (Part C), and one security is being placed directly into Stage IV (Part D). No securities are exiting the LT-ASM framework (Annexure II).
Key Points
- 5 new securities added to the LT-ASM framework effective March 12, 2026
- 2 securities moved to a higher ASM Stage (Stage 2)
- 0 securities moved to a lower ASM stage
- 1 security (Titan Biotech Ltd) placed directly into Stage IV per notice no. 20210604-41
- 0 securities are exiting the LT-ASM framework
- A consolidated list of all securities currently under LT-ASM (Annexure III) has been published
Regulatory Changes
Part A – Newly Added to LT-ASM
| Scrip Code | ISIN | Scrip Name |
|---|---|---|
| 539984 | INE799B01017 | Hindusthan Urban Infrastructure Ltd |
| 531288 | INE531D01010 | Lead Financial Services Ltd |
| 543545 | INE0ID001024 | Veerkrupa Jewellers Ltd |
| 539167 | INE347L01022 | Virat Leasing Ltd |
| 544726 | INE0J0B01017 | Kotyark Industries Limited |
Part B – Moved to Higher ASM Stage
| Scrip Code | ISIN | Scrip Name | Moved to Stage |
|---|---|---|---|
| 511246 | INE910D01024 | Bombay Talkies Ltd | 2 |
| 538894 | INE513C01010 | Octal Credit Capital Ltd | 2 |
Part C – Moved to Lower ASM Stage
Nil
Part D – Direct Placement into Stage IV
| Scrip Code | ISIN | Scrip Name | Stage |
|---|---|---|---|
| 524717 | INE150C01029 | Titan Biotech Ltd | 4 |
Annexure II – Securities Exiting LT-ASM
Nil
Compliance Requirements
- Traders and investors in the listed securities must be aware of the enhanced surveillance norms applicable under LT-ASM, which typically include restrictions such as mandatory additional margins, trade-for-trade settlement, or reduced price bands.
- Brokers must ensure clients trading in these securities are informed of and compliant with the applicable ASM-stage restrictions.
- No action is required for securities exiting the framework, as none are moving out this cycle.
Important Dates
- Effective Date: March 12, 2026 – All changes (additions, stage movements, direct placements) come into force.
Impact Assessment
The addition of five securities to the LT-ASM framework and the escalation of two securities to Stage 2 signals increased regulatory scrutiny due to abnormal price/volume movements or other risk indicators. Investors holding these stocks may face higher margins and restricted trading conditions. Titan Biotech Ltd’s direct placement into Stage IV represents the most stringent level of surveillance, significantly limiting trading flexibility. Market participants should review their exposure to all listed securities and prepare for associated compliance obligations effective March 12, 2026.
Impact Justification
Directly affects trading conditions for multiple securities by placing them under enhanced surveillance with stricter trading norms; impacts investors holding or trading these stocks.